# T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents

> **NCT00022763** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 52 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Enfuvirtide

## Key facts

- **NCT ID:** NCT00022763
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2004-12
- **Final completion:** —
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2016-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022763, "T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00022763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*